MX2020009045A - Procedimiento in vitro para detectar disfuncion de la barrera intestinal en animales mediante la determinacion de ovotransferrina. - Google Patents

Procedimiento in vitro para detectar disfuncion de la barrera intestinal en animales mediante la determinacion de ovotransferrina.

Info

Publication number
MX2020009045A
MX2020009045A MX2020009045A MX2020009045A MX2020009045A MX 2020009045 A MX2020009045 A MX 2020009045A MX 2020009045 A MX2020009045 A MX 2020009045A MX 2020009045 A MX2020009045 A MX 2020009045A MX 2020009045 A MX2020009045 A MX 2020009045A
Authority
MX
Mexico
Prior art keywords
ovotransferrin
animals
determining
intestinal barrier
vitro method
Prior art date
Application number
MX2020009045A
Other languages
English (en)
Inventor
Stefan Pelzer
Richard Ducatelle
Frank Thiemann
Monika Flügel
Immerseel Filip Van
Evy Goossens
Bart Devreese
Griet Debyser
Original Assignee
Evonik Operations Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evonik Operations Gmbh filed Critical Evonik Operations Gmbh
Publication of MX2020009045A publication Critical patent/MX2020009045A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306—Solid-phase reaction mechanisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54366—Apparatus specially adapted for solid-phase testing
    • G01N33/54386—Analytical elements
    • G01N33/54387—Immunochromatographic test strips
    • G01N33/54388—Immunochromatographic test strips based on lateral flow
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/79—Transferrins, e.g. lactoferrins, ovotransferrins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A40/00—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
    • Y02A40/70—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in livestock or poultry

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La presente invención se refiere a un procedimiento in vitro para detectar disfunción de la barrera intestinal en animales, el procedimiento comprende las siguientes etapas: a) recolectar material de muestra intestinal de un animal individual o de una población animal y b) determinar la cantidad de al menos un marcador de proteína contenido en dicho material de muestra; en donde el al menos un marcador de proteína comprende o consiste en ovotransferrina o un fragmento funcional de la misma, y en donde una cantidad aumentada de dicho al menos un marcador de proteína contenido en dicha muestra frente a una muestra de referencia indica disfunción de la barrera intestinal.
MX2020009045A 2018-03-02 2019-02-28 Procedimiento in vitro para detectar disfuncion de la barrera intestinal en animales mediante la determinacion de ovotransferrina. MX2020009045A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18159632 2018-03-02
PCT/EP2019/054947 WO2019166534A1 (en) 2018-03-02 2019-02-28 In vitro method for detecting intestinal barrier failure in animals by determining ovotransferrin

Publications (1)

Publication Number Publication Date
MX2020009045A true MX2020009045A (es) 2020-10-12

Family

ID=61569071

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020009045A MX2020009045A (es) 2018-03-02 2019-02-28 Procedimiento in vitro para detectar disfuncion de la barrera intestinal en animales mediante la determinacion de ovotransferrina.
MX2020009044A MX2020009044A (es) 2018-03-02 2019-02-28 Procedimiento in vitro para detectar disfuncion de la barrera intestinal en animales.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2020009044A MX2020009044A (es) 2018-03-02 2019-02-28 Procedimiento in vitro para detectar disfuncion de la barrera intestinal en animales.

Country Status (11)

Country Link
US (2) US20210011027A1 (es)
EP (2) EP3759496A1 (es)
KR (2) KR20200128412A (es)
CN (2) CN111801579A (es)
AR (1) AR114423A1 (es)
BR (2) BR112020017969A2 (es)
CA (2) CA3092472A1 (es)
MX (2) MX2020009045A (es)
RU (2) RU2770104C2 (es)
WO (2) WO2019166531A1 (es)
ZA (2) ZA202005890B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110832089A (zh) 2017-05-12 2020-02-21 赢创运营有限公司 用于检测动物中由产气荚膜梭菌诱导的疾病的方法
CA3092472A1 (en) * 2018-03-02 2019-09-06 Evonik Operations Gmbh In vitro method for detecting intestinal barrier failure in animals
CA3122457A1 (en) 2018-12-14 2020-06-18 Evonik Operations Gmbh In vitro method for detecting avian intestinal dysbiosis
EP4679086A1 (en) * 2023-03-10 2026-01-14 Meiji Co., Ltd Biomarker and use thereof
EP4679087A1 (en) * 2023-03-10 2026-01-14 Meiji Co., Ltd Biomarker and use thereof
EP4617666A1 (en) * 2024-03-11 2025-09-17 Impextraco NV Biomarkers for gastrointestinal diseases in animals

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0281251A3 (en) * 1987-02-04 1988-09-28 International Immunoassay Laboratories, Inc. A method for preparing a fecal sample composition for immunoassay testing
US5538851A (en) 1993-12-22 1996-07-23 Institut Pasteur And Cneva Primers for the amplification of genes coding for the enterotoxin and the lecithinase of Clostridium perfringens and their application to the determination of the presence and numeration of these bacteriae
US6218529B1 (en) 1995-07-31 2001-04-17 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
FR2788780B1 (fr) 1999-01-27 2001-03-30 Ap Cells Inc Procede de preparation de vesicules membranaires
GB9927320D0 (en) 1999-11-18 2000-01-12 Chiron Spa Exosome separation
UA78486C2 (uk) * 1999-12-10 2007-04-10 Хемджен Корпорейшн Композиція для перорального введення птахам та тваринам для лікування або зниження ризику інфекції травного тракту (варіанти), її застосування (варіанти) та спосіб лікування або зниження ризику інфекцій травного тракту (варіанти)
US6812023B1 (en) 2000-04-27 2004-11-02 Anosys, Inc. Methods of producing membrane vesicles
WO2003009704A2 (en) * 2001-07-27 2003-02-06 N.V. Nutricia Enteral compositions for the prevention and/or treatment of sepsis
US20040101860A1 (en) 2002-11-27 2004-05-27 Jones Alison M. Predicting animal performance
WO2005001483A2 (en) * 2003-06-27 2005-01-06 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts Methods for diagnisis and differential diagnosis of dementia disorders
WO2005019258A2 (en) 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US7374927B2 (en) 2004-05-03 2008-05-20 Affymetrix, Inc. Methods of analysis of degraded nucleic acid samples
US8252769B2 (en) * 2004-06-22 2012-08-28 N. V. Nutricia Intestinal barrier integrity
US20090208971A1 (en) * 2004-07-28 2009-08-20 Andreas Christ Insulin promoter factor 1 as target/marker of beta cell failure
US8058000B2 (en) 2005-06-02 2011-11-15 The United States Of America As Represented By The U.S. Environmental Protection Agency Species-specific primer sets and identification of species-specific DNA sequences using genome fragment enrichment
US20070042354A1 (en) 2005-08-19 2007-02-22 Engelhard Eric K Detecting pathogens in companion animals
JP5038407B2 (ja) * 2006-06-14 2012-10-03 ジョンズ ホプキンズ ユニバーシティー 疾患のバイオマーカーとしてのアルブミン結合性タンパク質／ペプチド複合体
KR100920971B1 (ko) 2007-03-08 2009-10-09 삼성에버랜드 주식회사 식품 위해 미생물 검출용 프라이머 및 이를 이용한 식품위해 미생물 검출방법
PL2164862T3 (pl) 2007-06-08 2015-12-31 Australian Poultry Crc Pty Ltd Toksyna netb z clostridium
US20100267062A1 (en) * 2007-09-26 2010-10-21 Norbert Frey Osteopontin as Novel Prognostic Biomarker for Heart Failure
EP2279403B1 (en) * 2008-05-05 2016-03-16 Los Alamos National Security, LLC Highly simplified lateral flow-based nucleic acid sample preparation and passive fluid flow control
US20160041153A1 (en) 2008-11-12 2016-02-11 Kirk Brown Biomarker compositions and markers
WO2010056337A2 (en) 2008-11-12 2010-05-20 Caris Mpi, Inc. Methods and systems of using exosomes for determining phenotypes
EP2393934A4 (en) * 2009-02-06 2012-08-29 Astute Medical Inc DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE
IT1406051B1 (it) * 2010-08-05 2014-02-06 D M G Italia S R L Uso di hmgb1 come marcatore biologico di infiammazione intestinale umana, metodo non invasivo per la sua rilevazione in campioni fecali e kit relativo.
EP2495025A1 (en) 2011-03-04 2012-09-05 Fresenius Medical Care Deutschland GmbH Filter for the removal of micro-vesicles from biological fluids, methods and devices using such a filter
EP3495497B1 (en) 2011-04-28 2021-03-24 Life Technologies Corporation Methods and compositions for multiplex pcr
RU2472162C1 (ru) * 2011-05-04 2013-01-10 Государственное научное учреждение Всероссийский научно-исследовательский институт экспериментальной ветеринарии им. Я.Р. Коваленко Россельхозакадемии Способ серологической диагностики вирусных желудочно-кишечных инфекций крупного рогатого скота методом иммуноферментного анализа
CN107080847A (zh) * 2011-06-24 2017-08-22 森彻斯有限公司 细胞外靶向药物缀合物
EP2626705A1 (en) * 2012-02-13 2013-08-14 Institut d'Investigacions Biomédiques August Pi i Sunyer Use of the soluble form of AXL in the diagnosis and/or prognosis of heart failure syndrome
US10114028B2 (en) * 2012-03-20 2018-10-30 Upstream Medical Technologies Limited Biomarkers for pneumonia and acute decompensated heart failure
CN102697812B (zh) 2012-05-28 2013-08-14 山东农业大学 鸡胆汁来源的胞外体提取方法及其在免疫学上的应用
CA2879337C (en) 2012-07-19 2021-11-30 Atlantic Cancer Research Institute Method for the isolation of microvesicles
PL2906238T3 (pl) 2012-10-02 2021-06-28 Oil-Dri Corporation Of America Produkt z gliny i jego zastosowania
KR101922128B1 (ko) 2012-12-04 2019-02-13 삼성전자주식회사 미세유동장치 및 이를 채용한 생물학적 시료 내의 표적 물질 농축방법
EP2746406B1 (en) 2012-12-18 2017-08-23 Samsung Electronics Co., Ltd. Composition and kit for diagnosing breast cancer including miRNAs within vesicle, and method of diagnosing breast cancer using the same
CN110106229B (zh) 2013-01-03 2023-03-28 外来体诊断公司 用于分离微囊泡的方法
JP2015039320A (ja) 2013-08-21 2015-03-02 日鉄住金環境株式会社 複数細菌の同時検出及び／又は定量方法
RU2016112915A (ru) * 2013-09-05 2017-10-09 Эф-Ай-Оу Корпорейшн Биомаркеры для раннего выявления критической или угрожающей жизни ответной реакции на заболевание и/или ответной реакции на лечение
WO2015103710A1 (en) 2014-01-13 2015-07-16 The Royal Institution For The Advancement Of Learning/Mcgill University Methods, reagents and kits for the assessment of bacterial infection
CA2955300A1 (en) 2014-07-16 2016-01-21 General Mills, Inc. Bulk allele discrimination assay
SMT202300116T1 (it) * 2014-08-06 2023-05-12 Envera Lic Llc Composizioni di spore batteriche per usi industriali
US20170269103A1 (en) * 2014-08-20 2017-09-21 Rhode Island Hospital Assessment of Heart Failure and Arrhythmic Risk Stratification by Measuring Circulating Hu Proteins
CN104531867B (zh) 2014-12-25 2017-03-29 湖北省农业科学院畜牧兽医研究所 产气荚膜梭菌肠毒素阳性菌双重荧光定量pcr快速检测试剂盒
EP3112474A1 (en) * 2015-06-29 2017-01-04 Evonik Degussa GmbH Method of detecting avian necrotic enteritis
WO2016201272A1 (en) 2015-06-12 2016-12-15 King Abdulaziz City For Science And Technology Method of diagnosing patients with conditions caused by mendelian mutations
CN105412319A (zh) * 2016-01-05 2016-03-23 邱钱勇 一种治疗慢性肾功能衰竭的中药制剂及其制备方法及应用
CN107090518B (zh) 2017-04-05 2020-03-20 苏州协云基因科技有限公司 腹泻相关病原体多重rt-pcr联合基因芯片检测试剂盒
CN110832089A (zh) 2017-05-12 2020-02-21 赢创运营有限公司 用于检测动物中由产气荚膜梭菌诱导的疾病的方法
WO2018206690A1 (en) 2017-05-12 2018-11-15 Evonik Degussa Gmbh Method for detecting c. perfringens induced diseases in animals
EP3692163A1 (en) 2017-10-02 2020-08-12 Evonik Operations GmbH In-process method for guiding measures against the propagation of salmonella and/or against the propagation of campylobacter in an animal flock
CA3092472A1 (en) 2018-03-02 2019-09-06 Evonik Operations Gmbh In vitro method for detecting intestinal barrier failure in animals
WO2019228961A1 (en) 2018-05-29 2019-12-05 Evonik Operations Gmbh In vitro method for monitoring the pathogen load in an animal population
KR20210021014A (ko) 2018-06-15 2021-02-24 에보니크 오퍼레이션즈 게엠베하 조류 집단에서의 괴사성 장염 돌발의 조기 검출 방법
CA3122457A1 (en) 2018-12-14 2020-06-18 Evonik Operations Gmbh In vitro method for detecting avian intestinal dysbiosis
CA3144035A1 (en) 2019-07-17 2021-01-21 Evonik Operations Gmbh Method for determining the risk of an avian pathogenic e. coli (apec) infection in an avian flock
EP4093886A1 (en) 2020-01-24 2022-11-30 Evonik Operations GmbH An epigenetic clock for galliformes

Also Published As

Publication number Publication date
CA3092472A1 (en) 2019-09-06
BR112020017969A2 (pt) 2020-12-22
CA3092519A1 (en) 2019-09-06
RU2020129391A3 (es) 2022-03-09
EP3759495A1 (en) 2021-01-06
KR20200128413A (ko) 2020-11-12
KR20200128412A (ko) 2020-11-12
BR112020017971A2 (pt) 2020-12-22
AR114423A1 (es) 2020-09-02
CN111801579A (zh) 2020-10-20
RU2020129391A (ru) 2022-03-09
CN111819444A (zh) 2020-10-23
RU2020129428A3 (es) 2022-03-09
RU2020129428A (ru) 2022-03-09
MX2020009044A (es) 2020-10-12
US12031991B2 (en) 2024-07-09
RU2770104C2 (ru) 2022-04-14
WO2019166534A1 (en) 2019-09-06
ZA202005887B (en) 2022-03-30
US20210011027A1 (en) 2021-01-14
ZA202005890B (en) 2022-12-21
EP3759496A1 (en) 2021-01-06
WO2019166531A1 (en) 2019-09-06
US20210003592A1 (en) 2021-01-07

Similar Documents

Publication Publication Date Title
MX2020009045A (es) Procedimiento in vitro para detectar disfuncion de la barrera intestinal en animales mediante la determinacion de ovotransferrina.
Moreno et al. Dopamine D1-histamine H3 receptor heteromers provide a selective link to MAPK signaling in GABAergic neurons of the direct striatal pathway
Alpár et al. Hypothalamic CNTF volume transmission shapes cortical noradrenergic excitability upon acute stress
PH12015502849B1 (en) Biomarkers for cognitive dysfunction diseases and method for detecting cognitive dysfunction disease using biomarkers
ES2572372T3 (es) Método de diagnóstico de enfermedades neurodegenerativas basado en la medición de los niveles o de la actividad de SIRT1
Lin et al. Cortical synaptic NMDA receptor deficits in α7 nicotinic acetylcholine receptor gene deletion models: implications for neuropsychiatric diseases
EP3755331A4 (en) AGONISTS OF THE STIMULATOR OF INTERFERON GENES (STING)
BR0206937B1 (pt) métodos de processar ovos tendo uma caracterìstica identificada, e de processar ovos de acordo com o gênero, aparelhos para extrair material de uma pluralidade de ovos, e material de um ovo, para ensaiar material extraìdo de uma pluralidade de ovos, e para processar seletivamente ovos, e, sistema de processamento de ovo.
EP4292654A3 (en) Detection of misfolded proteins
Sharrad et al. Quantitative immunohistochemical co-localization of TRPV1 and CGRP in varicose axons of the murine oesophagus, stomach and colorectum
EA202091937A1 (ru) Новые способы разведения и контролируемого высвобождения агентов биологического контроля
ZA201908057B (en) Method for detecting c. perfringens induced diseases in animals
MX2020003523A (es) Deteccion de dimetilarginina simetrica.
PE20210419A1 (es) Proteinas de union al receptor de cannabinoides tipo 1 (cb1) y usos de las mismas
IL280584A (en) Adjuvant effect of the tlr1/2 agonist diprovocim synergizes with checkpoint-inhibiting antibodies to eliminate disease
Dong et al. Modification of the plasma complement protein profile by exogenous estrogens is indicative of a compromised immune competence in marine medaka (Oryzias melastigma)
AR087654A1 (es) METODO DIAGNOSTICO DE ANIMALES VACUNADOS CON PESTIVIRUS QUIMERICO EN EL CUAL LA PROTEINA Eʳⁿˢ DEL VIRUS DE LA DIARREA VIRAL BOVINA (BVDV) ES REMPLAZADA POR PROTEINA Eʳⁿˢ DE PESTIVIRUS DE ANTILOPE AMERICANO
AR107440A1 (es) ANTICUERPOS MONOCLONALES ESPECÍFICOS PARA EL ANTÍGENO pIII DE ADENOVIRUS HUMANO (ADV), PRODUCIDOS Y SECRETADOS POR HIBRIDOMAS CELULARES, ÚTILES PARA LA DETECCIÓN Y EL DIAGNÓSTICO DE LA INFECCIÓN CAUSADA POR ADV
Miskimon et al. Selective expression of Narp in primary nociceptive neurons: Role in microglia/macrophage activation following nerve injury
EA201891170A1 (ru) Биомаркер поликистозной болезни почек и варианты его применения
EP1766095A4 (en) DETECTION OF PROTEIN TRANSLATION BY BETA GALACTOSIDASE REPORTER FRAGMENT COMPLEMENTATION
AR059326A1 (es) Resistencia a la mastitis
Matsuura et al. SIPA1L1/SPAR1 is a non-PSD protein involved in GPCR signaling
MX2024004130A (es) Sistema de produccion animal.
MX2019002932A (es) Biomarcadores proteicos para enfermedades asociadas con el sistema de activacion por contacto.